Get the Stockscreener App
14.65
0.34%
-0.05
Pre-market:
14.96
0.31
+2.12%
10 X Genomics Inc Stock (TXG) Latest News
10x Genomics, Inc. (TXG): Among Cathie Wood’s Top Stock Picks for 2025 - Yahoo Finance
10x, Harvard settle genomics patent dispute with Vizgen during trial - Reuters
10x Genomics, Harvard settle Vizgen patent dispute (TXG:NASDAQ) - Seeking Alpha
22,687 Shares in 10x Genomics, Inc. (NASDAQ:TXG) Acquired by China Universal Asset Management Co. Ltd. - MarketBeat
Chan Zuckerberg Initiative Launches Billion Cells Project with 10x Genomics and Ultima Genomics to Advance AI in Biology – Company AnnouncementFT.com - Financial Times
10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Seattle's Parse Biosciences lands another legal victory in patent dispute - The Business Journals
Parse Wipes Out 10x Genomics Patents Ahead of March Trial - Bloomberg Law
Cathie Wood's ARK buys Qualcomm and 10X Genomics stock - MSN
SG Americas Securities LLC Acquires 49,468 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10 Promising Biotech Stocks to Invest in (February 2025) - Securities.io
Slow Capital Inc. Has $310,000 Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
Genomics Market to Grow by USD 5.21 Billion (2024-2028), Boosted by Rising Investments in R&D, with AI Impacting Market TrendsTechnavio - Yahoo Finance
[Latest] Global Single Cell Multiomics Market Size/Share Worth USD 18.90 Billion by 2033 at a 19.58% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) - GlobeNewswire Inc.
After a Year of Launches, 10x Refocuses on Customer Support, Biopharma Market Growth - Genetic Engineering & Biotechnology News
10x Genomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025 - BioSpace
10x Genomics, Inc. (NASDAQ:TXG) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
TXG (10x Genomics) EV-to-EBIT : -8.44 (As of Jan. 24, 2025) - GuruFocus.com
10x Genomics (MEX:TXG) EV-to-EBITDA : -13.26 (As of Jan. 24, 2025) - GuruFocus.com
10x Genomics (NASDAQ:TXG) Shares Down 10%Here's Why - MarketBeat
Spatial Proteomics Market Report and Competitive Landscape 2025-2030, with 10X Genomics, Bruker, Fluidigm, Akoya Biosciences, PerkinElmer, Biotechne, S2 Genomics, Seven Bridges Genomics & More - Yahoo Finance
Weiss Ratings Reaffirms Sell (E+) Rating for 10x Genomics (NASDAQ:TXG) - MarketBeat
TXG (10x Genomics) Preferred Stock : $0.0 Mil (As of Sep. 2024) - GuruFocus.com
Avanza Fonder AB Takes Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
TXG (10x Genomics) Future Policy Benefits - GuruFocus.com
TXG (10x Genomics) EBIT per Share : $-1.47 (TTM As of Sep. 2024) - GuruFocus.com
TXG (10x Genomics) Shareholder Yield % : 0.44% (As of Sep. 2024) - GuruFocus.com
TXG (10x Genomics) Earnings Yield (Joel Greenblatt) % : -7.27% (As of Sep. 2024) - GuruFocus.com
10x Genomics (NASDAQ:TXG) Trading Down 4.9%What's Next? - MarketBeat
Assenagon Asset Management S.A. Makes New $26.31 Million Investment in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics (FRA:1KJ) Days Sales Outstanding : 53.41 (As of Sep. 2024) - GuruFocus.com
Mirador Capital Partners LP Boosts Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
The Analyst Verdict: 10x Genomics In The Eyes Of 6 Experts - Benzinga
JPMorgan Chase & Co. Has $8.03 Million Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics (NASDAQ:TXG) Shares Gap UpTime to Buy? - MarketBeat
Morgan Stanley Issues Pessimistic Forecast for 10x Genomics (NASDAQ:TXG) Stock Price - MarketBeat
10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2024 Results - The Malaysian Reserve
10x Genomics Q4 Revenue Hits $165M with Mixed Results: Services Surge 35% YoY Despite Overall Decline - StockTitan
Diversified Trust Co Invests $511,000 in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics Announces Mega-Scale Single Cell Analysis for One Cent Per Cell at Human Cell Atlas General Meeting - Kilgore News Herald
10x Genomics: Struggling Amid Operational Challenges (NASDAQ:TXG) - Seeking Alpha
Vizgen's Antitrust Claims Tossed From 10x, Harvard Patent Suit - Bloomberg Law
Vizgen Loses Antitrust Claims Against 10x In Biotech IP Fight - Law360
10x Genomics (NASDAQ:TXG) Shares Up 11.6%Here's What Happened - MarketBeat
10x Genomics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - StreetInsider.com
10x Genomics to Present at the 43rd Annual J.P. Morgan Healthcare Conference – Company Announcement - Financial Times
10x Genomics, Inc. (NASDAQ:TXG) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Cathie Wood's ARK ETF adjusts, adds 10X Genomics, sells Rocket Lab - Investing.com
8.82%
3.54%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):